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a b s t r a c t
Subunit vaccination modalities tend to induce particular immune effector responses. Viral vectors are
well known for their ability to induce strong T cell responses, while protein-adjuvant vaccines have been
used primarily for induction of antibody responses. Here, we demonstrate in mice using a Plasmodium
falciparum merozoite surface protein 1 (PfMSP1) antigen that novel regimes combining adenovirus and
poxvirus vectored vaccineswith protein antigen inMontanide ISA720 adjuvant can achieve simultaneous
antibody and T cell responseswhich equal, or in some cases surpass, the best immune responses achieved
by either the viral vectors or the protein vaccine alone. Such broad responses can be achieved either






vectors are admixed with protein and adjuvant, and were apparent despite the use of a protein antigen
that represented only a portion of the viral vector antigen. We describe further possible advantages of
viral vectors in achieving consistent antibody priming, enhanced antibody avidity, and cytophilic isotype
skew. These data strengthen the evidence that tailored combinations of vaccine platforms can achieve
desired combinations of immune responses, and further encourage the co-administration of antibody-
inducing recombinant protein vaccines with T cell- and antibody-inducing recombinant viral vectors as
ieveontanide
lasmodium falciparum
one strategy that may ach
. Introduction
The strong cellular immune responses induced by viral vec-
ors have encouraged their clinical development as candidate
accines against cancer and a number of intracellular pathogens,
otably pre-erythrocytic infection by Plasmodia, Mycobacterium
uberculosis (TB) and HIV-1 [1]. Recombinant protein-in-adjuvant
ormulations have remained predominant in efforts to induce
ntibody responses against extracellular pathogens, including
lood-stage malaria parasites [2]. Recently, replication-deﬁcient
iral-vectored vaccines encoding blood-stage malaria antigens
ave, like protein vaccines, proven protective in a rodent malaria
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model and induced promising in vitro activity in assays against
Plasmodium falciparum [3–6].
Combined cellular and humoral responses may be desirable
for maximal immune-mediated protective efﬁcacy in a number of
contexts, notably againstmalaria (bothpre-erythrocytic andblood-
stage) and HIV [6–9]. Despite the ongoing development of single
antigen, single formulation vaccines many speculate that the ﬁrst
highly efﬁcacious vaccine against P. falciparummalaria will require
a multi-antigen, multi-stage, or multi-formulation product [7].
Multiple strategies using heterologous prime-boost com-
binations of DNA, viral vectored and protein vaccines have
demonstrated capacity to induce combined antibody and cellular
responses in theHIVﬁeld.Adenovirusprime–proteinboost regimes
induce greatly enhanced antibody immunogenicity compared to
individual adenovirus or protein/adjuvant immunization, both in
guineapigs andprimates [10,11]. Similarly, replication-competent-
adenovirus prime–protein boost and triple platform DNA-Semliki
Open access under CC BY license. Forest virus–orthopoxvirus combinations have proven immuno-
genic and protective in amacaque SIVmodel [12,13]. DNA–protein
and DNA–poxvirus–protein candidate HIV-1 vaccine regimes have
also entered phase I and II clinical trials [14–17], and a regime com-
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eported to have induced partial protection against HIV-1 infection
n a phase III clinical trial in Thailand [18]. Although this particu-
ar result requires further conﬁrmation, it highlights the exciting
otential of regimes combining viral vectors and recombinant pro-
eins to induce protection against an immunologically challenging
arget.
In the malaria ﬁeld, such approaches have been less thoroughly
xplored. Results of efforts to combine viral vectors encoding
he pre-erythrocytic antigen circumsporozoite protein (CSP) with
he leading CSP-based vaccine RTS,S (a non-vectored recombinant
irus-like particle) have been mixed. A phase I/IIa clinical trial
f modiﬁed vaccinia virus Ankara (MVA)-CSP prime with RTS,S
oost did not enhance immunogenicity or protection beyond that
chievedbyRTS,S alone [19], in contrast to encouragingpre-clinical
bservations on the combination of MVA with hepatitis B surface
ntigen or Plasmodium berghei CSP proteins [20,21]. More recently,
macaquestudyusinganadenovirusvectored-CSPprimeandRTS,S
oost signiﬁcantly improved CD4+ T cell immunogenicity com-
ared to the individual vaccines used alone, but did not enhance
ntibody responses above those seen with RTS,S [22].
Merozoite surface protein 1 (MSP1) is a leading candidate anti-
en for use in subunit vaccination against blood-stage P. falciparum,
ith numerous MSP1-based vaccines under development [2,23].
accination with recombinantMSP1 can protect mice against Plas-
odium yoelii challenge and Aotus monkeys against P. falciparum
24,25]. It is generally thought that the principal mechanism of
SP1-induced immunity is blockade of erythrocyte invasion by
ntibodies to theC-terminalMSP119 moiety, though ithas alsobeen
emonstrated that antibodies can arrest growth at a stage after ery-
hrocyte invasion [26]. Antibodies against MSP119 are responsible
or a substantial proportion of the in vitro growth inhibitory activ-
ty of serum from individuals in P. falciparum endemic areas [27].
n addition to antibody, CD8+ T cell responses to MSP1 can provide
artial protective efﬁcacy against late liver-stage P. yoelii parasites
6,28], and CD4+ T cells speciﬁc to P. yoelii MSP133 can confer pro-
ection against blood-stage infection when adoptively transferred
nto mice in the absence of antibodies [29]. Protection in humans
gainst P. falciparum following whole-parasite immunization with
oth sporozoites and blood-stage parasites has been associated
ith T cell responses against blood-stage parasites, although drug
ersistence casts some doubt upon the results of the latter study
30–32]. In contrast, despite considerable effort andpromisinganti-
ody induction, protein-based subunit vaccines have so far failed to
nduce substantial protection against blood-stage P. falciparum [2].
We were therefore interested to compare antibody induction
y viral vectors head-to-head with protein-adjuvant vaccination,
nd to develop a regime which improved upon the antibody
nduction of our viral vectored regime while retaining its cellu-
ar immunogenicity. Adenovirus–MVA heterologous prime–boost
sing a PfMSP1 antigen insert is a leading viral vectored regime
or antibody and T cell induction against this blood-stage P. falci-
arum antigen [3,5]. As a protein-adjuvant comparator, we used a
ichia pastoris-expressed recombinant PfMSP119 [33], adjuvanted
y Montanide ISA720 (Seppic, France). Montanide ISA720 is a
qualene-based water-in-oil emulsion which has been shown to
e a potent adjuvant in both animal and human studies [34–37].
Here we describe and compare in detail the immunogenicity
f PfMSP1 vaccines using a novel combination of three subunit
accine platforms: simian adenovirus AdCh63 [5,38]; MVA; and
ecombinant protein in Montanide ISA720. We report that, when
ombined, these technologies can achieve simultaneous antibody
nd T cell responses which equal, or in some cases surpass, the
est immune responses achievedwith either technology alone.We
escribe in detail the responses induced, with data on antibody
sotypes and avidity, splenic antibody secreting cell counts, T cell
uality, and response longevity.28 (2010) 7167–7178
2. Materials and methods
2.1. Animals and immunizations
All procedures were performed in accordance with the terms
of the UK Animals (Scientiﬁc Procedures) Act Project Licence and
were approved by the University of Oxford Animal Care and Eth-
ical Review Committee. 5–6 weeks old female BALB/c (H-2d) and
C57BL/6 (H-2b) mice (Harlan Laboratories, Oxfordshire, UK) were
anesthetized before immunization with medetomidine (Domitor,
Pﬁzer) and ketamine (Ketaset, Fort Dodge) and revived subse-
quently with Antisedan reversal agent (Pﬁzer). All immunizations
were administered intramuscularly (i.m.) unless otherwise speci-
ﬁed, with vaccine divided equally into each musculus tibialis.
The creation of simian adenovirus 63 (AdCh63) and modiﬁed
vaccinia virus Ankara (MVA) vectors encoding the PfM128 anti-
gen is described elsewhere [5]. Brieﬂy, this antigen is a bi-allelic
fusion incorporating the MSP142 antigen from the K1/Wellcome
and 3D7/MAD20 P. falciparum strains fused in tandem alongside
four blocks of conserved sequence from the remainder of the 3D7
strain MSP1 molecule (blocks 1, 3, 5 and 12). The MVA used in
the current study differs from the previously published vector
[3] in that it lacked the green ﬂuorescent protein (GFP) marker.
To generate the markerless MVA expressing PfM128, the antigen
was cloned into a transient-dominant shuttle vector plasmid such
that PfM128 was expressed from the vaccinia P7.5 promoter, and
inserted into the TK locus of MVA. The plasmid also expresses a
GFPmarker [39]. This plasmidwas transfected into chicken embryo
ﬁbroblast cells (CEFs) infected with MVA expressing red ﬂuores-
cent protein (RFP), as previously described [3]. Recombinant MVAs
were generated by homologous recombination between regions of
homology at the TK locus of MVA and in the plasmid shuttle vec-
tor. Unstable intermediate recombinants expressing RFP and GFP
were selected using a MoFlo cell-sorter (Beckman Coulter, USA)
and plated out on CEFs. After 2–3 passages, further recombina-
tion between the repeated TK ﬂanking regions results in either
reversion to the starting virus (MVA–RFP) or formationof themark-
erless recombinant virus MVA-PfM128.White plaques (expressing
neither RFP nor GFP) were picked and puriﬁed. Presence of the
PfM128 antigen at the TK locus was conﬁrmed by sequencing and
PCR.
The protein vaccine used was mono-allelic Wellcome strain
MSP119 expressed in the yeast P. pastoris (kindly provided by A
Holder, NIMR, London) [33]. The full sequence of this antigen is rep-
resentedwithin the viral vector vaccines. Protein in endotoxin-free
PBS was mixed manually in a syringe immediately prior to immu-
nization with Montanide ISA720 adjuvant (SEPPIC, France), in the
ratio 3:7 as previously described [40]. Where applicable, viral vec-
tored vaccineswere incorporated in the protein-PBS fraction of this
mixture.
BALB/c mice were vaccinated at 8- or 14-week intervals with
doses as follows (unless otherwise speciﬁed): 1010 virus particles
(vp) for AdCh63; 107 plaque forming units (pfu) for MVA; and
20g of protein. C57BL/6 mice were vaccinated at 8-week inter-
vals with 108 vp AdCh63, 106 pfu MVA, or 5g protein. Blood was
obtained for immunological studies using tail bleeds 2 weeks after
each immunization and at later time points as described.
2.2. Ex vivo IFN and splenic antibody-secreting cell ELISPOT
Ex vivo IFN enzyme linked immunosorbent assays (ELISPOT)
wereperformedaspreviouslydescribed [41], usingpeptides appro-
priate to the mouse strain as follows: either the overlapping
peptides 90 and 91 (NKEKRDKFLSSYNYI and DKFLSSYNYIKDSID)
which comprise the immunodominant CD8+ T cell epitope in
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3D7 allele)-derived peptide 215 (TKPDSYPLFDGIFCS) recognised
y CD8+ T cells from C57BL/6 mice [5].
Antigen-speciﬁc splenic antibody secreting cells (ASCs) wereeasured as previously described [42]. In brief, nitrocellulose bot-
omed96-wellMultiscreenHAﬁltrationplates (Millipore,UK)were
oated with 5g/ml P. falciparum MSP-119 (Wellcome/FVO allele,
xpressed in Pichia) [33] and incubated overnight at 4 ◦C. Plates
ere washed twice with PBS and blocked for 1h at 37 ◦C, 5% CO2
ig. 1. Responses induced by two-immunization regimes. In ﬁgures throughout this repor
espectively. A dash is used to indicate separate sequential vaccinations whereas parenth
ollowed by protein, whereas ‘(A+P)’ indicates mixed adenovirus and protein given simu
ere 1010 virus particles (vp) for AdCh63; 107 plaque forming units (pfu) for MVA; and
symbols) and group mean (line). Error bars, where present, indicate 95% conﬁdence in
peciﬁed. Panel A: Comparison of total PfMSP119 speciﬁc IgG and PfMSP133 speciﬁc CD8
ose interval not done. Graph symbols indicate dose interval: () for 57 days; (×) for 97 d
ell (lower two panels) responses in adenovirus-primed BALB/cmice receiving different b
anel, the two lines illustrate responses with different dosing intervals, with graph symbo
FN secreting CD8+ T cell response to an MSP119 epitope (peptide 215), assessed by ELI
06 pfu MVA, and 5g protein. Panel D: C57BL/6 mice (n=6–18 per group) were immu
ith adenovirus–protein mixture. CD8+ T cell responses to peptide 215 were assessed by28 (2010) 7167–7178 7169
with D10 (MEM -modiﬁcation, 10% Fetal Calf Serum, 4mM l-
glutamine, 100U/ml penicillin and 100g/ml streptomycin (all
from Sigma, UK); and 50m 2-mercaptoethanol (Gibco)). 5×105
splenocytes were plated onto the pre-coated ELISPOT plate per
replicate well and serially diluted. Plates were incubated for 5h
at 37 ◦C, 5% CO2. Following incubation plates were washed twice
with PBS and incubated overnight at 4 ◦C with biotinylated anti-
mouse -chain speciﬁc IgG antibody (CALTAG, CA). Assays were
t, the abbreviations ‘A’, ‘M’ and ‘P’ are used in place of ‘AdCh63’, ‘MVA’ and ‘protein’,
eses and a+ sign indicates mixed vaccinations–for example, ‘A–P’ indicates AdCh63
ltaneously at the same site. Unless otherwise stated, mice were BALB/c and doses
20g for protein. In this and subsequent ﬁgures, all graphs plot individual values
terval for population mean. Throughout, group size n=6 except where otherwise
+ T cell responses measured by ICS 14 days post-boost in BALB/c mice. P–P 97 day
ays. Panel B: Illustration of timecourses of total IgG (upper two panels) and CD8+ T
oosting vaccines (MVA in left two panels; protein in right-hand two panels). In each
ls as in panel A. Panel C: C57BL/6 mice were immunized for examination of splenic
SPOT for optimal sensitivity 14 days after vaccination. Doses were 108 vp AdCh63,
nized as in Figure C, with the addition of a group receiving a single immunization
peripheral blood ICS 14 days after vaccination.














Fig. 2. Kinetics of responses to A–M–P (panel A) and A–P–M (panel B) three-stage
ere primed at day 0, with subsequent boosts on days 97 and 154, as indicated by
y ELISA. Lower panels depict PfMSP133 speciﬁc IFN+ CD8+ T cell responses assess
eveloped using colour developing agents (Bio-Rad AP conjugate
ubstrate kit) that were ﬁltered through a 0.2m ﬁlter (Sartorius,
K). ELISPOT plates were counted using AID plate reader software
AID, Cadama Medical) and counts were visually conﬁrmed. No
pots were observed in control wells containing splenocytes but
o coating antigen.
ig. 3. Comparison of responses of BALB/c mice to three component and two componen
eceiving three vaccinations were primed at day 0, with subsequent boosts on days 97 an
eceiving two vaccinations received these on days 97 and 154. This permitted all results
accination. All subsequent ﬁgures use data from the same groups of mice, with the exc
igure 2. Panel A: Total IgG responses assessed by ELISA. Panel B: IFN+ CD8+ T cell responization regimes in BALB/c mice. Regimes as described in legend to Fig. 1. All mice
vertical lines. Upper panels depict PfMSP119 speciﬁc total IgG responses assessed
ICS. Late time point T cell responses assayed by ELISPOT are presented in Fig. 5B.
2.3. Intracellular cytokine stainingThe percentage of peripheral blood and splenic CD8+ T cells
expressing IFN, TNF and IL-2 in response to 5h stimulation with
5g/ml peptides 90 and 91 was assessed by intracellular cytokine
staining as previously described [5]. Surface stainingwaswith anti-
t sequential regimes. Dosing was as described in legend to Fig. 1; n=6/group. Mice
d 154 (the same mice are depicted in Fig. 1 with 97 day interval and in Fig. 2). Mice
depicted in this ﬁgure to be obtained from synchronous assays 14 days after ﬁnal
eption of dose interval comparisons in Fig. 8 and low dose data in supplementary
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D8 PerCP-Cy5.5 and anti-CD4 Paciﬁc Blue while intracellular
taining was with anti-IFN APC, anti-TNF FITC and anti-IL-2 PE
all supplied by eBioscience, UK). Cytokine production frequency
n peptide-unstimulated control wells (which was typically <0.1%)
as subtracted from the result in peptide-stimulatedwells prior to
urther analysis. The gating strategy is illustrated in supplementary
igure 1.
.4. Antibody responses—total IgG, isotypes and avidity
Total IgG and isotype ELISA were carried out as previously
escribed using bacterially expressed GST-tagged PfMSP119 (Well-
ome/FVO allele) as the coating antigen [5].
Antibody avidity was assessed by sodium thiocyanate (NaSCN)-
isplacementELISA [43].Usingpreviouslymeasured total IgGELISA
iters, sera were individually diluted to a level calculated to give
titer of 1:300 and plated at 50l/well in 16 wells of a 96 well
late. Following incubation and washing, an ascending concen-
ration of the chaotropic agent NaSCN was added down the plate
0–7MNaSCN). Plateswere incubated for 15min at room tempera-
ure beforewashing anddevelopment as for total IgG. The intercept
f the OD405 curve for each sample with the line of 50% reduction
f the OD405 in the NaSCN-free well for each sample (i.e. the con-
entration of NaSCN required to reduce the OD405 to 50% of that
ithout NaSCN) was used as a measure of avidity.
.5. Statistical analysis
Statistical analysis was carried out using Prism 5 software
GraphPad, La Jolla, CA, USA). All ELISA titers were log10 trans-
ormedprior to analysis. Graphs indicate sample arithmeticmeans;
rror bars where present indicate 95% conﬁdence intervals for
he population arithmetic mean. One-way ANOVA was used
or comparing normally distributed data with Bonferroni’s mul-
iple comparison post-test for comparison of speciﬁc groups;
ruskal–Wallis tests were used for comparison of non-normally
istributed data with Dunn’s multiple comparison post-test for
omparison of speciﬁc groups. Two-way ANOVA was used for
omparison of groups differing in two factors. Two-way repeat
easures ANOVAwas used for comparison of responses measured
or different groups at different time points, after the exclusion
f the small number of mice for which replicate data were not
ig. 4. Comparison of responses of BALB/c mice to three component sequential and two-
o Fig. 3 with doses as in legend to Fig. 1. This permitted all results depicted in this ﬁgur
roups A–M–P and A–P–M are as displayed in Fig. 3, repeated here for clarity. Panel A: To
y ICS.28 (2010) 7167–7178 7171
available at all time points. P<0.05 was taken to be statistically
signiﬁcant throughout.
3. Results
3.1. Immunogenicity of two component regimes
The experimental design provided replicate groups receiv-
ing AdCh63–MVA (A–M) and AdCh63–protein (A–P) sequential
regimes at 57 day and 97 day intervals. Antibody and IFN+ CD8+
T cell responses induced by these regimes are illustrated in Fig. 1.
These data were analyzed by two-way ANOVA, demonstrating that
antibody responses 14 days post-boost were greater with the A–P
regime than the A–M regime (Fig. 1A) (P<0.0001), and greater
with the 97 day interval than the 57 day interval (P=0.0006).
The antibody response induced by protein–protein (P–P) vacci-
nation was markedly variable with three mice mounting high
responses comparable to those receiving A–P immunization, and
three very weakly responding mice (Fig. 1A and B). There was
no signiﬁcant difference between median antibody responses fol-
lowing protein–protein, adenovirus–MVA and adenovirus–protein
regimes after a 57 day dose interval (P=0.37 by Kruskal–Wallis
test), but there was a clear increase in the variance of the response
after two shot protein regimes compared to viral-vector containing
regimes.
In contrast with the antibody results, greater percentages of
IFN+ CD8+ T cells were detected by ICS 14 days after A–M immu-
nization than A–P, and the 57 day dose interval was superior
(P<0.0001 for both comparisons) (Fig. 1A and B). Clear boosting of
CD8+ T cell responses by MVA was evident at both dose intervals.
As expected, given the lack of the CD8+ T cell epitope in theMSP119
protein sequence in BALB/c mice [5], CD8+ T cell responses were
not detectable following P–P vaccination. Additional experiments
in C57BL/6 mice (in which a CD8+ T cell epitope is present in the
MSP119 protein [5]) conﬁrmed that, in contrast to the A–M regime,
P–P vaccination did not induce a CD8+ T cell response detectable
by IFN splenic ELISPOT or peripheral blood ICS, and that CD8+ T
cell responses were unaltered by A–P immunization as compared
to adenovirus priming alone (Fig. 1C and D). CD8+ T cell responses
after A–P immunization of either mouse strain thus presumably
represent the contracting or effector memory CD8+ T cell response
induced by the adenovirus.
stage mixed-component regimes. Vaccination regimes were as described in legend
e to be obtained from synchronous assays 14 days after ﬁnal vaccination. Data for
tal IgG responses assessed by ELISA. Panel B: IFN+ CD8+ T cell responses assessed


























































Fig. 5. Persistent immune responses20weeks afterﬁnal vaccination inBALB/cmice.
Mice and regimes were as described in legend to Fig. 3. Panel A: Total IgG responses
assessed by ELISA. Panel B: IFN secreting CD8+ T cell responses assessed by ex vivo
splenic ELISPOT. SFU= spot forming units. Panel C: Comparison of reduction in log
IgG titer between 14 and 137 days after ﬁnal vaccination with different regimes.172 A.D. Douglas et al. / Va
.2. Immunogenicity of three-component sequential regimes
We subsequently compared the immunogenicity of three-
omponent sequential adenovirus–MVA–protein (A–M–P) and
denovirus–protein–MVA (A–P–M) regimes to two-component
egimes (Figs. 2 and 3). The kinetics of the responses induced by
hese regimes were markedly different. We found that addition of
rotein to adenovirus–MVA (A–M–P) was able to boost antibody
ut not CD8+ T cell responses (again as would be predicted due
o lack of the T cell epitope in this protein) (Fig. 2A), while addi-
ion of MVA to adenovirus–protein (A–P–M) boosted CD8+ T cell
esponses but not antibody titer (Fig. 2B). Total IgG responses to
–M–P and A–P–M were signiﬁcantly higher than those to A–M
P<0.05 by ANOVA with Bonferroni post-test), with no signiﬁ-
ant differences between the responses to A–M–P, A–P–M and A–P
P>0.05, Fig. 3A). There were no statistically signiﬁcant differences
n CD8+ T cell responses between A–M–P, A–P–M and A–M regimes
P>0.05 by ANOVA with Bonferroni post-test, Fig. 3B). In general,
ny two- or three-component regime including AdCh63 and MVA
nduced maximal CD8+ T cell responses as measured in the blood.
onversely, maximal IgG responses were elicited by any regime
ncluding AdCh63 and protein.
.3. Regimes mixing viral-vectored and protein-adjuvant
accines
We continued to investigate whether the advantages of three-
omponent regimes could be achieved in a simpliﬁed two-stage
egime, by mixing protein and adjuvant with one or both viral
ector components (Fig. 4A and B). We found that there was
o signiﬁcant difference by Kruskal–Wallis test between the
hree-immunization regimes and a two-immunization regime
ixing protein and Montanide ISA720 with both adenovirus
rime and MVA boost. Interestingly, there was a small but
tatistically signiﬁcant increase in CD8+ T cell responses and
ecrease in antibody responses with the (A+P)–M regime rel-
tive to A–P–M (P<0.05, ANOVA with Bonferroni post-test).
ntibody responses tended to be highest with the three com-
onent regimes, or when protein-adjuvant was co-administered
ith both viral vectors. Interestingly, in C57BL/6 mice, (A+P)
riming induced modestly but signiﬁcantly higher CD8+ T cell
esponses than adenovirus alone (Fig. 1D, P=0.04, Mann–Whitney
est).
Thus a simpliﬁed two-shot immunization regimeappearshighly
mmunogenic andmixingof theviral vectorswithprotein andadju-
ant did not appear to affect vector potency, a result which may
ncourage development of further strategies combining vectors
ith protein and adjuvant, including homologous vector–protein
rime–boost immunization regimes.
.4. Longevity of responses
Serum antibody and splenic T cell responses were assayed by
LISA and IFN ELISPOT138days after ﬁnal vaccination for selected
roups of mice (Fig. 2 D291 time point and Fig. 5). Antibody
esponses toA–M–PandA–P–Mremained signiﬁcantly higher than
hose for A–M (P<0.05 for both comparisons by Kruskal–Wallis
est with Dunn’s multiple comparison post-test), while CD8+ T cell
esponses following A–M–P and A–M remained greater than those
or A–P (P<0.01 and P<0.05 respectively by the same method).
here was a mean drop of 0.4 log units in ELISA titer between
4 and 138 days after ﬁnal vaccination, with no signiﬁcant dif-
erence in this rate of decline between groups (Fig. 5C, P=0.37
y Kruskal–Wallis test). Thus, as was the case with early post-
accination responses, maximal long-lived IgG responses were
etectedwith any regime including AdCh63 and protein, while any
























rig. 6. Comparison of intradermal and intramuscular injection route for AdCh63 an
ither receiving both vectors i.d. or both vectors i.m. All mice received a third vacci
gG responses assessed by ELISA. Panel B: IFN+ CD8+ T cell responses assessed by I
egime including AdCh63 and MVA induced maximal long-lived
D8+ T cell responses in the spleen.
.5. Immunization routes and doses
We also compared the antibody and CD8+ T cell responses of
ix mice receiving the A–M–P regime entirely intramuscularly ver-
us six mice receiving the viral-vector components intradermally
i.d.) (Fig. 6). There was no signiﬁcant difference by t-test between
he two groups’ log ELISA titer (P=0.26) or % IFN+ CD8+ T cells
P=0.20) 14 days after ﬁnal vaccination, norwas a difference found
etween groups for either ELISA or CD8+ T cell responses by repeat
easures ANOVA taking into account all time points up to 14 days
fter ﬁnal vaccination.
In parallel, we had conducted the same experiments at lower
accine doses (108 vp AdCh63, 106 pfu MVA, and 5g protein
t 8-week intervals) in BALB/c mice, in case a ‘ceiling’ or max-
mum dose–response effect prevented us observing differences
etween the higher dose regimes used in the previous experiments
supplementary Figure 2A and B). Importantly, similar patterns
ig. 7. Titers of IgG1 and IgG2aweremeasured separately by isotype-speciﬁc ELISA,
sing sera taken frommicewhich had received ﬁve different vaccination regimes at
wo time points (14 and 137 days after ﬁnal vaccination). Vaccination regimes were
s described in legend to Fig. 3 with doses as in legend to Fig. 1. Data are plotted as
atio of log titer of IgG2a/IgG1.A. BALB/c mice were immunized with adenovirus 1×1010 vp and MVA 1×107 pfu,
with 20g protein i.m. Timing was as described in legend to Fig. 3. Panel A: Total
to those previously observed were apparent from the lower dose
experiment. As expected all antibody and T cell responses were
substantially weaker when using lower vaccine doses. Responses
to protein–protein vaccination were markedly more variable than
responses to adenovirus-containing regimes. At these lower doses,
addition of protein did not enhance the antibody immunogenicity
of viral vector regimes,withnosigniﬁcantdifferences inELISA titers
following A–M, A–P, A–M–P or A–P–Mvaccination. T cell responses
were again substantially higher in the A–M, A–M–P and A–P–M
groups than in the A–P group. As before, the (A+P)–M, A–(M+P) and
(A+P)–(M+P) two-stage regimes mixing viral and protein vaccines
produced results similar to three-stage vaccination, with a trend
towards higher antibody but lower CD8+ T cell responses in the
group receiving (A+P)–(M+P). Thusdespite the clearly sub-maximal
responses achieved in these animals (in particular with the pro-
tein only vaccination), regimes incorporating adenovirus and MVA
again appeared to result inmore consistent combined antibody and
CD8+ T cell responses to the antigen.
3.6. Antibody isotypes
To further characterize the immune responses to the various
vaccine modalities, we performed IgG isotype ELISAs. It was not
possible tomeasure isotype-speciﬁc titers for the three P–P immu-
nized mice with low total IgG ELISA titers. Bearing in mind this
limitation, viral-vector-containing regimes induced a signiﬁcantly
greater ratio of IgG2a to IgG1 than was present in the high-total-
titer P–P immunizedmice, and that the IgG2a/IgG1 ratiowas higher
for all groups 137 days rather than 14 days after the ﬁnal vaccina-
tion, corresponding to bettermaintenance of the titer of IgG2a than
IgG1 over time (Fig. 7; P<0.001 for both comparisons by repeated
measures two-way ANOVAwith Bonferroni’s post-test). There was
no interaction of time and regime (i.e. no inter-regime differences
in the rate of change of the IgG isotype balance over time).3.7. Antibody avidity
We continued to investigate the responses to the various
regimes by measuring antibody avidity using NaSCN antibody-
displacement ELISA for selected groups and time points (Fig. 8A–C).













ﬁig. 8. Antibody avidity was measured as the concentration of NaSCN required to r
s described in legend to Fig. 3 with doses as in legend to Fig. 1. Panel A: Avidity 2
ntervals. Individual values (symbols) and mean (line) are plotted for each group. P
re plotted for each group. Panel C: Correlation between total IgG ELISA titer and avmong mice receiving A–M and A–P regimes, we observed that
ice receiving A–M had higher antibody avidity 14 days post-
oost than those receiving A–P, without any signiﬁcant difference
etween 57 day and 97 day dose interval (Fig. 8A; P=0.024 for
egime comparison, P=0.33 for comparison dose interval by two-
ig. 9. Antigen-speciﬁc antibody secreting cells (ASCs) were measured by ex vivo uncult
roups receiving different vaccination regimes. Vaccination regimes were as described in
etween regimes. Individual values (symbols) andmedian (line) are plotted for each grou
nal vaccination. Line is best-ﬁt linear regression line.OD405 by 50% relative to sample OD405 without NaSCN. Vaccination regimes were
after boosting in mice receiving A–M and A–P regimes at 57 day and 97 day dose
: Comparison of avidity between regimes and over time. Arithmetic mean values
measurements of total IgG and avidity are plotted for each individual mouse.way ANOVA). Looking more widely at mice receiving A–M–P,
A–P–M, A–M, A–P and P–P regimes, it was apparent that there was
a trend for higher avidity in mice receiving any regime including
both viral vectors (A andM) than in those receiving only A–P or P–P
(Fig. 8B).When analyzed by two-way repeatmeasures ANOVA, this
ured ASC ELISPOT 137 days after ﬁnal vaccination in a random four mice from ﬁve
legend to Fig. 3 with doses as in legend to Fig. 1. Panel A: Comparison of ASC counts
p. Panel B: Relationship of log transformed ASC count and ELISA titer 137 days after
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iig. 10. Intracellular cytokine staining allowed detection of cells producing combin
ith doses as in legend to Fig. 1. Gating strategy is illustrated in supplementary Figu
r positive for a second cytokine (usually TNF) 2 weeks after ﬁnal vaccination. Pr
ells which were positive for two cytokines.
rend did not reach statistical signiﬁcance (P=0.32) without pool-
ng of replicate groups (described above for A–P and A–M), though
here was a signiﬁcant increase in avidity over time after ﬁnal vac-
ination across all groups (P<0.0001). There was no correlation
etween total IgG ELISA titer and avidity, either when data from
ll time points were combined (Fig. 8C, r2 = 0.00, P=1.00 by lin-
ar regression) or where each time point was analyzed separately
data not shown). Thus antibody avidity and total IgG ELISA titer
ppear to vary independently, and avidity appears to rise over time
ost-boost and with MVA-containing regimes.
.8. Splenic antibody secreting cells
At the conclusion of the experiment (138 days after ﬁnal
accination), mice were sacriﬁced and antigen-speciﬁc antibody
ecreting cells (ASCs) in the spleens of four mice from each group
ere counted using an ex vivo assay without a proliferative cul-
ure step (Fig. 9). This non-cultured assay at such a late time point
ould be expected to detect the presence of long-lived plasma
ells. Log transformedASC counts differed between groups (P=0.04
y Kruskal–Wallis test) with a trend towards the highest ASC
ounts in groups receiving three component regimes (A–M–P and
–P–M), and the lowest ASC count in mice receiving A–M. Differ-
nces between individual groups however did not reach statistical
igniﬁcance after correcting formultiple comparisons usingDunn’s
ost-test. There was a reasonable linear correlation between log
ransformed ASC counts and log transformed total IgG ELISA titers,
resent using either peak ELISA titer 14 days after ﬁnal vaccination
data not shown), or late ELISA titer 138 days after ﬁnal vaccination
Fig. 9B, for late time point, r2 = 0.39, P=0.004).
.9. T cell functionality
The ICS antibody panel stained for IFN, TNF and IL-2, thus
llowing quantiﬁcation of single, double and triple cytokine pos-
tive antigen-speciﬁc CD8+ T cells in the blood at the time points
ssayed. Results 2 weeks after ﬁnal vaccination are displayed in
ig. 10. Given the lack of a CD8+ T cell epitope in the protein vaccine,
he A–P group can be viewed as an unboosted control. Themajority
f T cells positive for a single cytokine were IFN+. Those posi-
ive for a second cytokine weremostly IFN+ TNF+, in accordance
ith previous observations using viral-vector P. yoeliiMSP142 vac-
ines [6]. Few cells expressing IL-2were observedwith any regime.
omparing the various three-stage and two-stage regimes includ-
ng both adenovirus and MVA, although there was some variations of IFN, TNF and IL-2. Vaccination regimes were as described in legend to Fig. 3
anel A: Proportions of CD8+ T cells positive for at least one cytokine (usually IFN)
d using SPICE software (M. Roederer, NIH, USA). Panel B: Proportions of all CD8+ T
between regimes in the proportion of double cytokine positive
cells relative to single positive cells (Fig. 10A), there was no dif-
ference in the proportion of double cytokine positive cells as a
percentage of all CD8+ T cells (Fig. 10B) (P=0.13 by ANOVA). Thus
encouragingly, admixing viral vectors with protein-adjuvant did
not affect either T cell quantity (Fig. 4B) or functional “quality”,
demonstrating the potential at least in mice for these subunit vac-
cine platforms to be combined and administered using a single
formulation.
4. Discussion
Adenoviral prime–MVA boost regimes induce antibody and
CD8+ T cell responses equivalent or superior to a range of het-
erologous and homologous adenovirus-only two-stage regimes[5],
making this immunization approach the current ‘gold-standard’
among adeno- and pox-viral vectored regimes. This study primar-
ily sought to assess whether the antibody immunogenicity of our
existing A–M PfMSP1 regime could be enhanced by the addition of
a protein-adjuvant vaccine component, and has demonstrated that
an encouraging combination of cellular and humoral responses can
be achieved by this three-platform strategy.
The protein available to us – a Pichia produced, sequence-
unmodiﬁed PfMSP119 originally used in an NMR structural study
– is likely to be conformationally accurate [33]. Good correla-
tions between anti-PfMSP119 ELISA titer and IgG-mediated in vitro
growth inhibitory activity (GIA) against P. falciparum strains have
previously been demonstrated both for our viral vectored vaccines
and for a range of protein PfMSP119 vaccines [5,44]. Direct GIA
measurement was not possible with the small quantities of mouse
serum available in this study.
As the protein antigen used here was only a portion of the viral-
vector antigen, caution is necessary in the interpretation of our
results. Although the use of BALB/c mice facilitated the investiga-
tion of antibody responses,whichwas our primary aim, someof the
studiesundertakenhere couldhavebeneﬁted fromdetectable T cell
responses against the MSP119 moiety, which is small and poorly
processed [45]. In future studies PfMSP142 might be preferable as
a protein antigen due to the known induction of T cell responses
against MSP133 epitopes in P. yoelii and P. falciparum as well as
against PfMSP133 in humans [5,6,46].
Despite this, our results clearly show that protein did not prime
orboost appreciableCD8+ T cell responses inC57BL/6mice inwhich
a CD8+ T cell epitope is present in PfMSP119. However, we have not





























































o176 A.D. Douglas et al. / Va
djuvant mixing on CD8+ T cell responses when there is a CD8+ T
ell epitope in a larger protein antigen that is less refractory to anti-
en processing. There is a possibility that CD4+ T cell responses at
ub-detectable levels to epitopes present in the viral vector antigen
ut absent from the protein antigen may have contributed to the
eliability of the viral vector priming, although the superior reli-
bility of viral vector priming does not seem to be unique to this
ntigen (de Cassan et al., unpublished observations).
.1. Antibody immunogenicity of triple platform regimes
Our results demonstrate that adenovirus is a highly reliable
rimer of antibody and CD8+ T cell responses. All 48 mice primed
ith 1010 vp of adenovirus had detectable antibody responses fol-
owing a single vaccination,whichwere reliably boosted byMVAor
rotein. In contrast, recombinant protein vaccines requiremultiple
oses to achieve consistently high antibody titers: ﬁve doses of P.
oelii MSP119 in Freund’s adjuvant are required for high and pro-
ective antibody titres [24] and three doses of RTS,S are required
o achieve optimal titres in humans [47]. Although some mice
eceiving P–P in this study achieved high antibody titers, there was
onsiderable variation within this regime.
Once responses were primed by adenovirus, protein appeared
o be the optimal platform for boosting antibody responses with
ntibody titers after A–P exceeding those following A–M. Three-
omponent regimes could also achieve simultaneous antibody and
ntigen-speciﬁc CD8+ T cell responses which equalled both anti-
ody induction by adenovirus–protein and CD8+ T cell induction by
–M—hitherto the best regimes available. This pattern remained
nchanged at time points up to 138 days after the ﬁnal vacci-
ation. Virus like particles (VLPs) are a fourth clinically relevant
accine platform, noted for their ability to induce strong antibody
esponses. Adenovirus–MVA–VLP combinations may have poten-
ial to improve further upon the antibody results achieved here,
hile maintaining or enhancing viral-vector induced CD4+ and
D8+ T cell responses.
In the absence of a vaccine which protects humans against
lood-stage P. falciparum, it is not yet fully understood which
ttributes of an antibody response are protective. In animal chal-
enge models the induction of high antibody concentrations seems
o be the principal predictor of MSP1 and AMA1 vaccine-mediated
rotection [48,49]. Most published work in the ﬁeld simply uses
LISA titer as a quantitative readout of antibody induction. There
re a further four quantitative properties of the vaccine-induced
ntibody response which we believe to be of interest: isotype
alance; antibody avidity; rate of decline of ELISA titer; and
ecall response to re-exposure to antigen. The current results
emonstrate signiﬁcant differences between the viral vectored
fMSP1-based vaccines and the protein-adjuvant PfMSP119 vac-
ine in some of these attributes. These may be due to differences
etween viral vector and recombinant protein delivery platforms
r differences in the processing and inherent antigenicity of the
ifferently sized antigens.
There are conﬂicting data regarding the importance of Fc-
ependent functions of Th1-type cytophilic antibody subclasses
human IgG1 and IgG3; murine IgG2a and IgG2b) in protection
gainst blood-stage malaria, and the impact of Th1 cytokines and
gG isotype on protective efﬁcacy [50–53]. However, the balance of
vidence now appears to support an important role of antibody–Fc
eceptor interactions in the response to the MSP1 and MSP3 anti-
ens [54,55], andantibody-dependent respiratoryburst production
y neutrophils has been shown to correlatewith protection against
linical malaria [56]. Protein-adjuvant vaccines often elicit rela-
ively Th2 skewed responseswith littlemurine IgG2a/b production
57]. Thus the signiﬁcant enhancement of IgG2a production we
bserved with viral vectors here may be of protective value, par-28 (2010) 7167–7178
ticularly if it generalizes to other antigens postulated to induce
Fc-dependent responses.
Antibody avidity has not been demonstrated to correlate with
protection against blood-stage malaria and has in fact been pre-
dicted to beunimportant in response tomerozoite antigens [48,58].
The relationship between avidity and protection in other diseases
is complex and variable, but avidity has been observed to be associ-
ated with protection against respiratory syncytial virus, HIV-1 and
anthrax [59–62]. The ﬁnding of enhanced avidity with A–M and
related regimes compared to protein vaccination therefore merits
further study and may be of interest beyond the malaria ﬁeld.
There was strikingly little variation in the rate of decline of total
IgG ELISA titer over the prolonged period of follow-up after vacci-
nation. It would therefore seem that peak ELISA titer is an adequate
predictor of antibody concentration at a later time point. The pres-
ence of a correlation between splenic ASC counts and ELISA titer at
both early and late time points supports this. The reliable priming
of antibody responses by adenovirus prior to subsequent boosting
by MVA or protein strongly suggests that adenovirus containing
regimes reliably generate memory B cell responses. It remains to
be seen whether the different vaccinemodalities investigated here
induce memory B cell/antigen-recall responses that vary indepen-
dently of peak antibody titer/overall regime immunogenicity.
It is interesting to note that in our previous studies, the viral
vector PfMSP1-based antigen failed to induce detectable antigen-
speciﬁc CD4+ T cell responses in BALB/c mice, even though viral
vectored regimes can induce measurable CD4+ T cell responses
against other antigens [5,6,63]. This would appear at odds with
our ﬁnding of a reliably primed and boosted, avid, IgG2a skewed
response to A–M-containing regimes: a response which bears the
hallmarks of a Th1 response to a ‘T-dependent’ antigen bearing
CD4+ T cell epitopes. Quite possibly, such helper T cell responses
were simply below the limit of detection of the ICS assay, or these
cells secreted cytokines other than IFN, TNF and IL-2. Alterna-
tively, recent evidence shows that, inmice, IFN- or IFN-activated
DCs can drive T-independent immunoglobulin class-switching
with either a Th1 or Th2 skew, and that T-independent type-2 anti-
gens can induce long-lived cells capable of mounting a secondary
recall response [64,65]. It is therefore possible that adjuvants (and
viral vectors) may be able to inﬂuence class-switching in a CD4+ T
cell-independent manner.
4.2. Optimised regimes for clinical trials
Previous studies have demonstrated that addition of protein
to DNA or MVA vaccines can enhance both antibody and T cell
immunogenicity (but without investigating mixtures of recom-
binant adenoviruses and protein) [20]. The current study is not
directly comparable due to its use of a different antigen and T cell
assay (ICS), but given that adenovirus–MVA prime–boost gener-
ally results in higher antibody and T cell responses than DNA–MVA
vaccination [66,67], it seems likely that the three-platform regimes
reported here would out-perform combinations of DNA, MVA and
protein.
Increasing the complexity of a viral vector vaccine regime by
addition of protein and adjuvant components would clearly have
cost implications, but these may be offset if fewer vaccine doses
are required due to enhanced immunity induced. It has been
reported elsewhere that the aluminium-based adjuvant Adjuphos
can enhance responses from an AdHu35 vectored vaccine [68].
Our results with a two-shot regime co-administering viral vec-
tor and protein-Montanide ISA720 vaccines demonstrate that such
admixture need not adversely affect the immunogenicity of either
component, and that increasing thebreadthof an immune response
need not come at the cost of a regime which requires logistically
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hat (A+P) primingmay enhance CD8+ T cell responses above those
nduced by adenovirus alone merits further study.
The applicability of this triple-platform approach to human vac-
ination requires further investigation. Optimal doses in different
pecies are usually not simply proportionate to body weight. We
ave used relatively highmouse doses to explore what are likely to
e the maximal responses obtainable with each vaccine platform.
lthough it is possible that protein doses larger than the 20g
sed here could result in more reliable priming (and doses up to
60g have been used in human trials [69]), 20g is commonly
sed for mouse studies in this ﬁeld [24]. It is worth noting that
ean antibody titers inmice receiving a low-doseA–P regimewere
omparable to those in mice receiving a high-dose 20g protein-
nly P–P regime (Fig. 1A and supplementary Figure 2), although
iters were more variable in the latter group. Regimes combining
iral vectors and protein may therefore achieve a protein dose-
paring effect (high-dose viral vector, low-dose protein may prove
ptimal).
Overall this study has provided a detailed description of the
mmunogenicity of adenovirus–poxvirus–protein triple platform
accination regimes, which we believe are likely to offer signiﬁ-
ant improvement upon the already promising results of previous
ector–protein combinations.Wehave therefore progressed to test
hese resultswithother antigens and in larger animal species. Itwill
lso be important to test the protective efﬁcacy of such regimes,
ither using rodent malaria antigens or possibly using P. berghei
arasites transgenic for PfMSP119 [70,71]. There are strong animal
nd human data to support the importance of antibody concentra-
ion, CD4+ and CD8+ T cell responses in protection against malaria
6,29–31,72]. Given the failure to achieve protection of humans
ith PfMSP1-based protein vaccines to date [2], we propose that
xperimental vaccines should aim formaximal breadth of antibody
nd T cell responses; breadth which we have demonstrated can
e achieved, along with potentially beneﬁcial changes in avidity
nd isotype, by three component regimes including adenovirus,
VA and protein. Our favoured regime for a clinical trial of this
pproach would be either adenovirus or adenovirus/protein mix
rime, followed by MVA/protein mix boost (with the choice of
rime depending onwhether protein dose-sparingwas a consider-
tion). These approaches require only a brief andpractical two-shot
accination regime, while achieving optimal T cell and antibody
esponses simultaneously.
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